Functional dynamic compartmentalization of respiratory chain intermediate substrates: implications for the control of energy production and mitochondrial diseases.
Activity defects in respiratory chain complexes are responsible for a large variety of pathological situations, including neuromuscular diseases and multisystemic disorders. Their impact on energy production is highly variable and disproportional. The same biochemical or genetic defect can lead to large differences in clinical symptoms and severity between tissues and patients, making the pathophysiological analysis of mitochondrial diseases difficult. The existence of compensatory mechanisms operating at the level of the respiratory chain might be an explanation for the biochemical complexity observed for respiratory defects. Here, we analyzed the role of cytochrome c and coenzyme Q in the attenuation of complex III and complex IV pharmacological inhibition on the respiratory flux. Spectrophotometry, HPLC-EC, polarography and enzymology permitted the calculation of molar ratios between respiratory chain components, giving values of 0.8:61:3:12:6.8 in muscle and 1:131:3:9:6.5 in liver, for CII:CoQ:CIII:Cyt c:CIV. The results demonstrate the dynamic functional compartmentalization of respiratory chain substrates, with the existence of a substrate pool that can be recruited to maintain energy production at normal levels when respiratory chain complexes are inhibited. The size of this reserve was different between muscle and liver, and in proportion to the magnitude of attenuation of each respiratory defect. Such functional compartmentalization could result from the recently observed physical compartmentalization of respiratory chain substrates. The dynamic nature of the mitochondrial network may modulate this compartmentalization and could play a new role in the control of mitochondrial respiration as well as apoptosis.
Benard
G
G
INSERM U688 Physiopathologie Mitochondriale, 146 rue Léo-Saignat, F-33076 Bordeaux Cedex, France.
Faustin
B
B
Galinier
A
A
Rocher
C
C
Bellance
N
N
Smolkova
K
K
Casteilla
L
L
Rossignol
R
R
Letellier
T
T
D000818:Animals; D045304:Cytochromes c / Q000502:physiology*; D004579:Electron Transport / Q000502:physiology*; D014450:Electron Transport Complex III / Q000037:antagonists & inhibitors; D003576:Electron Transport Complex IV / Q000037:antagonists & inhibitors / Q000378:metabolism; D008297:Male; D008689:Methacrylates / Q000494:pharmacology; D008930:Mitochondria, Liver / Q000378:metabolism; D008931:Mitochondria, Muscle / Q000378:metabolism; D028361:Mitochondrial Diseases / Q000188:drug therapy* / Q000503:physiopathology*; D010101:Oxygen Consumption; D011190:Potassium Cyanide / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D013844:Thiazoles / Q000494:pharmacology; D014451:Ubiquinone / Q000502:physiology*
D008689:Methacrylates; D013844:Thiazoles; D014451:Ubiquinone; C030517:myxothiazol; D045304:Cytochromes c; D003576:Electron Transport Complex IV; D014450:Electron Transport Complex III; D011190:Potassium Cyanide